Desipramine
As of the edition of 20 October 2026, Desipramine is a small molecule: marketed, first approved in 1982 (US); acts on SLC6A2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Norpramin
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 1 region
- Holder of the most recent approval
- Validus Pharmaceuticals; 2 holders in all
- Registered trials
- 33, 5 stopped early
- Disease areas
- Mental health; Chemically induced; Cancer; Nervous system; Digestive system; Immune system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Desipramine.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | P23975 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 4 | 1 | 3 |
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 10 | 9 | 0 | 1 |
| Phase 3 | 5 | 5 | 0 | 0 |
| Phase 4 | 4 | 3 | 0 | 1 |
| All trials | 33 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Validus Pharmaceuticals | Acquired holder | 2021 to now |
| Sanofi | Applicant and Later holder |